
2025 in Review丨Dual Harvest for China Innovative Drugs — How R&D Leadership Met Capital Validation
The year 2025 marked a profound paradigm shift for China’s innovative drug industry. We witnessed…

The year 2025 marked a profound paradigm shift for China’s innovative drug industry. We witnessed…

For decades, “Made in China” in pharmaceuticals conjured images of generic drugs and manufacturing scale.…

The National Medical Products Administration (NMPA) of China has officially approved Tibremciclib Capsules (BPI-16350, brand…

🫁 Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by persistent airflow…

Primary hypertension remains one of the most widespread chronic conditions globally. 👉 Currently, approximately 1.2…

The National Medical Products Administration (NMPA) has officially approved the marketing application for Mazdutide Injection…

In the fast-evolving landscape of lung cancer treatment, targeted therapies have reshaped the meaning of…

Cancer remains one of the most significant global health challenges, affecting millions of people every…

🍔 In recent years, the prevalence of metabolic disorders has continued to rise, driven by…

Acute ischemic stroke remains a major global health challenge, leading to high morbidity, mortality, and…